Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4
This analysis estimated that cost per treated patient, cost per complete responder, and cost per month in PFS for cilta-cel were remarkably lower than for DPd or PVd, highlighting the substantial clinical and economic benefit of cilta-cel for patients with RRMM.
Authors
- Saad Z. Usmani (ORCID: https://orcid.org/0000-0002-5484-8731)
- Sundar Jagannath (ORCID: https://orcid.org/0000-0003-2934-6518)
- Eileen Zhang
- Omar Castañeda Puglianini
- Xiaoxiao Lu (ORCID: https://orcid.org/0000-0001-8972-431X)
- Zaina Parvez Qureshi (ORCID: https://orcid.org/0000-0003-3231-0049)
- Sonja Sorensen
- Stephen Huo
- Doris K. Hansen
- Yan Zhang (ORCID: https://orcid.org/0000-0002-4835-8541)
Institutions
- Ithaka Harbors (US)
- Johnson & Johnson (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Moffitt Cancer Center (US)
- Janssen (United States) (US)
- Janssen Scientific Affairs (United States)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-08-21
- DOI
- https://doi.org/10.3389/fimmu.2024.1408892
- Citations
- 7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.98
Funders
- Amgen
- Sanofi
- Gilead Sciences
- Celgene
- Karyopharm Therapeutics
- Array BioPharma
- Regeneron Pharmaceuticals
- Adaptive Biotechnologies
- Janssen Scientific Affairs
- SkylineDx
- Genentech
- Pharmacyclics
- Legend Biotech
- Johnson and Johnson Pharmaceutical Research and Development